ES2191944T3 - Forma cristalina de la sal de sodio de omeprazol. - Google Patents

Forma cristalina de la sal de sodio de omeprazol.

Info

Publication number
ES2191944T3
ES2191944T3 ES98931166T ES98931166T ES2191944T3 ES 2191944 T3 ES2191944 T3 ES 2191944T3 ES 98931166 T ES98931166 T ES 98931166T ES 98931166 T ES98931166 T ES 98931166T ES 2191944 T3 ES2191944 T3 ES 2191944T3
Authority
ES
Spain
Prior art keywords
sodium salt
omeprazol
crystal form
omeprazole
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98931166T
Other languages
English (en)
Inventor
Anders Gustavsson
Kristina Kjellbom
Ingvar Ymen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2191944T3 publication Critical patent/ES2191944T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a una nueva forma de sal sódica del 5-metoxi-2-[[(4-metoxi-3,5-dimetil-2-piridinil)metil]sulfinil]-1H-bencimidazol, conocido con el nombre genérico de sal sódica de omeprazol. Esta invención también se refiere al procedimiento para la preparación de la forma sódica B de omeprazol que es termodinámicamente estable, así como las composiciones farmacéuticas que lo contienen y su empleo en el tratamiento de trastornos gastrointestinales.
ES98931166T 1997-06-27 1998-06-11 Forma cristalina de la sal de sodio de omeprazol. Expired - Lifetime ES2191944T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702483A SE510643C2 (sv) 1997-06-27 1997-06-27 Termodynamiskt stabil omeprazol natrium form B

Publications (1)

Publication Number Publication Date
ES2191944T3 true ES2191944T3 (es) 2003-09-16

Family

ID=20407555

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98931166T Expired - Lifetime ES2191944T3 (es) 1997-06-27 1998-06-11 Forma cristalina de la sal de sodio de omeprazol.

Country Status (35)

Country Link
US (1) US6207188B1 (es)
EP (2) EP1186602A3 (es)
JP (1) JP3377218B2 (es)
KR (1) KR100580987B1 (es)
CN (1) CN1134432C (es)
AR (1) AR013350A1 (es)
AT (1) ATE233756T1 (es)
AU (1) AU750239B2 (es)
BR (1) BR9810483A (es)
CA (1) CA2294614C (es)
CZ (1) CZ296723B6 (es)
DE (1) DE69811892T2 (es)
DK (1) DK0991641T3 (es)
EE (1) EE03613B1 (es)
EG (1) EG24224A (es)
ES (1) ES2191944T3 (es)
HK (1) HK1026699A1 (es)
HU (1) HU227976B1 (es)
ID (1) ID24829A (es)
IL (2) IL133559A0 (es)
IS (1) IS1946B (es)
MY (1) MY127871A (es)
NO (1) NO318245B1 (es)
NZ (1) NZ501929A (es)
PL (1) PL190869B1 (es)
PT (1) PT991641E (es)
RU (1) RU2186778C2 (es)
SA (1) SA98190410B1 (es)
SE (1) SE510643C2 (es)
SK (1) SK283958B6 (es)
TR (1) TR199903270T2 (es)
TW (1) TW483758B (es)
UA (1) UA58556C2 (es)
WO (1) WO1999000380A1 (es)
ZA (1) ZA985317B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
WO2000071122A1 (en) * 1999-05-20 2000-11-30 Par Pharmaceutical, Inc. Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
EP1706397A4 (en) * 2000-05-15 2007-08-01 Ranbaxy Lab Ltd AMORPHOUS FORM OF OMEPRAZOLE SALTS
CA2417311C (en) 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
CA2419067C (en) 2000-08-18 2008-12-23 Takeda Chemical Industries, Ltd. Injectable composition comprising benzimidazole compound and strong alkali
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP1411900B2 (en) * 2001-06-01 2013-12-04 Pozen, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
KR100433735B1 (ko) * 2001-06-27 2004-06-04 주식회사 씨트리 결정형 ⅰ을 갖는 란소프라졸의 제조방법
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
EP1556043A1 (en) * 2002-10-22 2005-07-27 Ranbaxy Laboratories, Ltd. Amorphous form of esomeprazole salts
WO2004099181A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
FR2871800B1 (fr) * 2004-06-17 2006-08-25 Sidem Pharma Sa Sa Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique
CA2570795C (en) * 2004-06-24 2013-05-28 Astrazeneca Ab Process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
US8247566B2 (en) * 2005-06-08 2012-08-21 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
CN101412710B (zh) * 2008-12-16 2010-04-21 海南百那医药发展有限公司 一种奥美拉唑钠化合物及其制法
EP2445344A4 (en) * 2009-06-25 2013-01-23 Pozen Inc METHOD FOR THE TREATMENT OF A PATIENT REQUIRED BY ASPIRIN THERAPY
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
CN102351846B (zh) * 2011-09-07 2012-08-22 周晓东 一种新的奥美拉唑钠化合物及其药物组合物
CN102319223B (zh) * 2011-09-21 2013-06-19 石药集团欧意药业有限公司 一种埃索美拉唑冻干制剂及其制备方法
CN102512380B (zh) * 2011-12-20 2013-04-17 海南锦瑞制药股份有限公司 一种以奥美拉唑钠为活性成分的冻干粉针剂及其制备方法
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102827147B (zh) * 2012-09-13 2013-08-07 山东罗欣药业股份有限公司 一种奥美拉唑钠晶体化合物及含有该晶体化合物的药物组合物
CN102871973A (zh) * 2012-10-16 2013-01-16 浙江亚太药业股份有限公司 一种奥美拉唑钠冻干制剂及其制备方法
CN103012371B (zh) * 2013-01-05 2014-02-12 宁辉 奥美拉唑钠结晶化合物、其制备方法及其药物组合物
CN103570687B (zh) * 2013-11-15 2015-01-07 悦康药业集团有限公司 一种奥美拉唑钠晶体化合物
CN104788426B (zh) * 2015-04-02 2015-12-30 天津大学 一种奥美拉唑钠半水合物及其制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2719916A1 (de) * 1977-05-04 1978-11-09 Kali Chemie Pharma Gmbh Verfahren zur herstellung von 2,9-dioxatricyclo eckige klammer auf 4,3,1,0 hoch 3,7 eckige klammer zu decanen
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
ES2023778A6 (es) * 1990-12-12 1992-02-01 Genesis Para La Investigacion Procedimiento para preparar sales alcalinas del omeprazol
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
WO1995032957A1 (en) * 1994-05-27 1995-12-07 Astra Aktiebolag Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles
DK0723436T3 (da) 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
CN1042423C (zh) * 1995-05-25 1999-03-10 常州市第四制药厂 奥美拉唑盐水合物及其制备方法
WO1998040377A1 (en) * 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose
EP0968205A1 (en) * 1997-03-07 2000-01-05 A/S GEA Farmaceutisk Fabrik Process for the preparation of 2- (2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B

Also Published As

Publication number Publication date
CA2294614A1 (en) 1999-01-07
EP0991641A1 (en) 2000-04-12
DK0991641T3 (da) 2003-05-19
EE03613B1 (et) 2002-02-15
CN1261362A (zh) 2000-07-26
TR199903270T2 (xx) 2000-07-21
HU227976B1 (en) 2012-07-30
EP0991641B1 (en) 2003-03-05
AU8135398A (en) 1999-01-19
MY127871A (en) 2006-12-29
HUP0003017A2 (hu) 2001-06-28
NO996440D0 (no) 1999-12-23
IL133559A (en) 2006-04-10
PT991641E (pt) 2003-06-30
RU2186778C2 (ru) 2002-08-10
CA2294614C (en) 2002-01-08
SE510643C2 (sv) 1999-06-14
IL133559A0 (en) 2001-04-30
AR013350A1 (es) 2000-12-27
UA58556C2 (uk) 2003-08-15
EE9900593A (et) 2000-08-15
EP1186602A2 (en) 2002-03-13
KR20010014165A (ko) 2001-02-26
ATE233756T1 (de) 2003-03-15
SK283958B6 (sk) 2004-06-08
BR9810483A (pt) 2000-09-12
AU750239B2 (en) 2002-07-11
PL190869B1 (pl) 2006-02-28
SE9702483L (sv) 1998-12-28
NZ501929A (en) 2001-06-29
NO996440L (no) 2000-02-08
HK1026699A1 (en) 2000-12-22
WO1999000380A1 (en) 1999-01-07
IS5314A (is) 1999-12-21
PL337735A1 (en) 2000-08-28
DE69811892T2 (de) 2004-03-04
JP2001508805A (ja) 2001-07-03
JP3377218B2 (ja) 2003-02-17
SE9702483D0 (sv) 1997-06-27
TW483758B (en) 2002-04-21
SA98190410B1 (ar) 2006-06-10
HUP0003017A3 (en) 2002-01-28
ID24829A (id) 2000-08-24
NO318245B1 (no) 2005-02-21
DE69811892D1 (de) 2003-04-10
US6207188B1 (en) 2001-03-27
SK172999A3 (en) 2000-07-11
CN1134432C (zh) 2004-01-14
CZ469999A3 (cs) 2000-08-16
EG24224A (en) 2008-11-10
IS1946B (is) 2004-10-13
KR100580987B1 (ko) 2006-05-17
ZA985317B (en) 1999-01-11
EP1186602A3 (en) 2002-03-27
CZ296723B6 (cs) 2006-05-17

Similar Documents

Publication Publication Date Title
ES2191944T3 (es) Forma cristalina de la sal de sodio de omeprazol.
ES2195345T3 (es) Nueva forma de s-omeprazol.
DE69811868D1 (de) Neue kristalline Form von Omeprazol
AR010361A1 (es) "S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS"
BR0007647A (pt) Sal de potássio de forma b de (s) -omeprazol, processo para a preparação do mesmo, formulação farmacêutica, uso do sal de potássio da forma b de (s) -omeprazol, e, método de tratamento de distúrbios gastrointestinais
BR0209103A (pt) Omeprazol forma c, processo para preparação e uso do mesmo e formulação farmacêutica
AR016700A1 (es) Omeprazol forma a cristalina. proceso para su preparacion, formulaciones farmaceuticas que lo contienen, y uso del mismo
YU32301A (sh) Novi kristalni oblik omeprazola
TH57762B (th) เกลือโพแทสเซียมของ (s)-โอมีพราโซล